NASH is the most rapidly growing aetiology for liver failure and indication for liver transplantation in the United States. Non゛lcoholic fatty liver disease (NAFLD) is associated with obesity, type 2 diabetes, dyslipidaemia and metabolic syndrome. Because of the absence of approved pharmacotherapy, ...
Rezdiffra Approved as First Drug for Nonalcoholic Fatty Liver Disease (NASH) In March, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra (resmetirom) for adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis. NA...
In March 2024, resmetirom was approved for use (under accelerated approval) in conjunction with diet and exercise for the treatment of adults with noncirrhotic NASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis) in the USA. Resmetirom is also under ...
metabolic disorders and cardiovascular diseases. Moreover,nonalcoholic steatohepatitis (NASH)is at the increasing risks of progressing to liver fibrosis ,cirrhosis,end⁃stage liver disease and even hepatocellular carcinoma(HCC). So far,neither the European drug administration ...
odevixibat in the USA and > 50 other countries, and in May 2017 was issued a method-of-treatment patent for odevixibat in PFIC and other specified liver diseases in the USA, corresponding method-of-use patents in Europe and Japan, and a method-of-treatment patent in NASH in the USA ...
36. Nash GK. Does dietary flaxseed oil have a role in prostate cancer?Clin Advis. 2007;10(3):119-120. 37. Demark-Wahnefried W, Polascik TJ, George SL, et al. Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery.Cancer Epidem...
October 2023: Novartis received approval from the US Food and Drug Administration (FDA) for Cosentyx (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. Cosentyx is one of the first FDA-approved fully human biologics that directly inhibits interleukin-17A (IL-17A),...
A rapid synthesis of febuxostat, a drug for gout and hyperuricemia, is also demonstrated.A CLIPA final example of a thiazole containing drug is given in the novel xanthine oxidase inhibitor febuxostat (359, Uloric) which was approved by the FDA in 2009. This inhibitor works by blocking ...
In 2019, FDA approved new indications for canagliflozin to reduce the risk of ESRD, kidney function deterioration, cardiovascular death and hospitalization for heart failure in patients with T2DM and CKD. Subsequently, based on the findings of the CREDENCE trial, the American Diabetes Association (ADA...
In the Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) trial, 173 patients between 8 and 17 years of age with NASH were randomized to receive natural vitamin E 800 units/day, metformin 1,000 mg/day, or placebo for 96 weeks. Vitamin E was similar to placebo in reducing...